[ACX 2026] Will the FDA approve a psilocybin treatment during 2026?

The market indicates low likelihood for FDA approval of psilocybin treatment in 2026.

With a market probability of 13.94% for approval, the consensus leans heavily towards a NO outcome. The Pulse AI probability is slightly higher at 17.44%, suggesting some optimism, but overall confidence remains moderate at 55/100.

• 1 Current market sentiment strongly favors a NO outcome.
• 2 The gap between market and AI probabilities indicates some uncertainty.
• 3 Confidence level suggests moderate belief in current market pricing.
• 4 Time to expiry is substantial, allowing for potential developments.
• 5 Historical context shows limited FDA approvals for similar treatments.